Pharmacokinetic drug–drug interactions with methotrexate in oncology

References

• Chabner B, Roberts Jr TG. Chemotherapy and the war on cancer. Nat. Rev. Cancer5, 65–72 (2005).
   PubMed Web of Science ®Google Scholar
• Crom WR. Methotrexate. In: A Clinician’s Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Grochow LB, Ames MM (Eds). Williams & Wilkins, MD, USA, 311–330 (1998).
   Google Scholar
• Messmann RA, Allegra CJ. Antifolates. In: Cancer Chemotherapy and Biotherapy. Chabner BA, Longo DL (Eds). Lippincott Williams & Wilkins, PA, USA, 139–184 (2001).
   Google Scholar
• Buchen S, Ngampolo D, Melton RG et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br. J. Cancer92, 480–487 (2005).
   PubMed Web of Science ®Google Scholar
• Fukuhara K, Ikawa K, Morikawa N, Kumagai K. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J. Clin. Pharm. Ther.33, 677–684 (2008).
   Google Scholar
• Trevino LR, Shimasaki N, Yang W et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol.27, 5972–5978 (2009).
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Martin-Guerrero I, Ballesteros J et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukaemia. Pediatr. Blood Cancer57, 612–619 (2011).
   PubMed Web of Science ®Google Scholar
• Crews KR, Liu T, Rodriguez-Galindo C et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer100, 1724–1733 (2004).
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang S-M, Tweedie DJ et al.; for the the International Transporter Consortium. Membrane transporters in drug development. Nat. Rev. Drug Discover.9, 215–236 (2010).
   PubMed Web of Science ®Google Scholar
• Mutsaers HAM, van den Heuvel LB, Ringens LH et al. Uremic toxins inhibit transport by breast resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PloS One6, e18438 (2011).
   PubMed Web of Science ®Google Scholar
• Abe T, Unno M, Onogawa T et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology120, 1689–1699 (2001).
   PubMed Web of Science ®Google Scholar
• Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, Sugiyama Y. Prediction of in vivo biliary clearance from in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol. Pharmacol.66, 450–459 (2004).
   PubMed Web of Science ®Google Scholar
• van de Steeg E, van der Kruijssen CM, Wagenaar E et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab. Dispos.37, 277–281 (2009).
   PubMed Web of Science ®Google Scholar
• Hooijberg JH, Broxterman HJ, Kool M et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res.59, 2532–2535 (1999).
   PubMed Web of Science ®Google Scholar
• Ito KI, Oleschuk CJ, Westlake C, Vasa MZ, Deeley RG, Cole SPC. Mutation of Trp1254 in the multispecific organic anion transporter multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J. Biol. Chem.276, 38108–38114 (2001).
   PubMed Web of Science ®Google Scholar
• Hulo JS, Villard E, Maguy A et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet. Genomics15, 277–285 (2005).
   Google Scholar
• Chen ZC, Lee K, Walther S et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res.62, 3144–3150 (2002).
   PubMed Web of Science ®Google Scholar
• Kool M, van der Linden M, de Haas M et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl Acad. Sci. USA96, 6914–6919 (1999).
   PubMed Web of Science ®Google Scholar
• Breedveld P, Zelcer N, Pluim D et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug–drug interactions. Cancer Res.64, 5804–5811 (2004).
   PubMed Web of Science ®Google Scholar
• Cha SH, Sekine T, Fukushima JI et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol.59, 1277–1286 (2001).
   PubMed Web of Science ®Google Scholar
• Takeda M, Khamdang S, Narikawa S et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther.302, 666–671 (2002).
   PubMed Web of Science ®Google Scholar
• Nozaki Y, Kusuhara H, Endou H, Sugiyama Y. Quantitative evaluation of the drug–drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J. Pharmacol. Exp. Ther.309, 226–234 (2004).
   PubMed Web of Science ®Google Scholar
• Richelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J. Natl Cancer Inst.99, 592–600 (2007).
   Google Scholar
• Lemachatti J, Levêque D, Beretz L, Bergerat JP. Potential pharmacokinetic interactions affecting antitumour drug disposition in cancer patients. Anticancer Res.29, 4741–4744 (2009).
   PubMed Web of Science ®Google Scholar
• Benet L, Hoerner BA. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther.71, 115–121 (2002).
   PubMed Web of Science ®Google Scholar
• Bourré-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J. Rheumatol.37, 1416–1421 (2010).
   PubMed Web of Science ®Google Scholar
• Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet1, 256–258 (1986).
   PubMed Web of Science ®Google Scholar
• Nozaki Y, Kusuhara H, Kondo T et al. Species differences in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther.322, 1162–1170 (2007).
   PubMed Web of Science ®Google Scholar
• El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP)2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther.320, 229–235 (2007).
   PubMed Web of Science ®Google Scholar
• Dean R, Nachman J, Lorenzana AN. Possible methotrexate-mezlocillin interaction. Am. J. Pediatr. Hematol. Oncol.14, 88–89 (1992).
   Google Scholar
• Ronchera CL, Hernandez T, Peris JE et al. Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther. Drug Monit.15, 375–379 (1993).
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Sawada Y, Matsushita Y, Moriwaki K, Bessho F, Iga T. Delayed elimination of methotrexate associated with piperacillin administration. Ann. Pharmacother.31, 1261–1262 (1997).
   PubMed Web of Science ®Google Scholar
• Zarychanski R, Wlodarczyk K, Ariano R, Bow E. Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate. J. Antimicrob. Chemother.58, 228–230 (2006).
   PubMed Web of Science ®Google Scholar
• de Miguel D, Garcia-Suarez J, Martin Y, Gil-Fernandez JJ, Burgaleta C. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol. Dial. Transplant23, 3762–3766 (2008).
   PubMed Web of Science ®Google Scholar
• Titier K, Lagrange F, Péhourcq F, Moore N, Molimard M. Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther. Drug Monit.24, 570–572 (2002).
   PubMed Web of Science ®Google Scholar
• Dalle J-H, Auvrignon A, Vassal G, Leverger G. Interaction between methotrexate and ciprofloxacin. J. Pediatr. Hematol. Oncol.24, 321–322 (2002).
   PubMed Web of Science ®Google Scholar
• Blum R, Seymour JF, Toner G. Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Ann. Oncol.13, 327–330 (2002).
   PubMed Web of Science ®Google Scholar
• Thyss A, Milano G, Renée N, Cassuto-Viguier E, Jambou P, Soler C. Severe interaction between methotrexate and a macrolide-like antibiotic. J. Natl Cancer Inst.85, 582–583 (1993).
   Google Scholar
• Shamash J, Joel S, Lundholm L, Millard L, Oliver T. High-dose methotrexate clearance following prior vancomycin administration: no significant interaction in the absence of overt renal impairment. Ann. Oncol.43, 169–170 (2003).
   Google Scholar
• Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination. Am. J. Med.123, 182.e1–182.e7 (2010).
   Web of Science ®Google Scholar
• Seithel A, Eberl S, Singer K et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos.35, 779–786 (2007).
   PubMed Web of Science ®Google Scholar
• Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother. Pharmacol.33, 82–84 (1993).
   PubMed Web of Science ®Google Scholar
• Whelan J, Hoare D, Leonard P. Omeprazole does not alter plasma methotrexate. Cancer Chemother. Pharmacol.33, 88–89 (1999).
   Google Scholar
• Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann. Pharmacother.34, 1024–1027 (2000).
   PubMed Web of Science ®Google Scholar
• Tröger U, Stötzel B, Martens-Lobenhoffer J, Gollnick H, Meter FP. Drug points: severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br. Med. J.324, 1497 (2002).
   PubMed Web of Science ®Google Scholar
• Joerger M, Huitema A, Van den Bongard H et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br. J. Clin. Pharmacol.62, 71–80 (2005).
   Google Scholar
• Bauters TGM, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm. World Sci.30, 316–318 (2008).
   PubMed Web of Science ®Google Scholar
• Suzuki K, Doki K, Homma M et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br. J. Clin. Pharmacol.67, 44–49 (2009).
   PubMed Web of Science ®Google Scholar
• Santucci R, Levêque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res.30, 3807–3810 (2010).
   PubMed Web of Science ®Google Scholar
• Santucci R, Levêque D, Kemmel V et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res.30, 963–966 (2010).
   PubMed Web of Science ®Google Scholar
• Aherne GW, Piall E, Marks V, Mould G, White WF. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br. J. Med.1, 1097–1099 (1978).
   PubMed Web of Science ®Google Scholar
• Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6) mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther.311, 228–236 (2004).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kusuhara H, Watanabe T et al. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug–drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab. Dispos.39, 1031–1038 (2011).
   PubMed Web of Science ®Google Scholar
• van Hest RM, Schnog JB, van’t Veer MB, Cornelissen JJ. Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated by imatinib. Am. J. Hematol.83, 757–758 (2008).
   Google Scholar
• Scholler J, Levêque D. Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans. Oncol. Rev.5, 77–92 (2011).
   Google Scholar
• Relling MV, Pui CH, Sandlund JT et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet356, 285–290 (2000).
   PubMed Web of Science ®Google Scholar
• Riva M, Landonio G, Defanti CA, Siena S. The effect of anticonvulsant drugs on blood levels of methotrexate. J. Neurooncol.48, 249–250 (2000).
   PubMed Web of Science ®Google Scholar
• Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA. Transcriptional profiling of genes induced in the livers of patients treated by carbamazepine. Clin. Pharmacol. Ther.80, 440–456 (2006).
   PubMed Web of Science ®Google Scholar